Early short-term imatinib treatment is sufficient to prevent the development of chronic allograft nephropathy

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 3026-3032

  Savikko, Johanna ^a,b   Rintala, Jukka M ^a   Rintala, Sini E ^a   Koskinen, Petri K ^a,c   Von Willebrand, Eva ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

chronic allograft nephropathy; imatinib; kidney transplantation; platelet derived growth factor

Indexed keywords

CREATININE; CYCLOSPORIN; CYCLOSPORIN A; IMATINIB; PLATELET DERIVED GROWTH FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG TOLERABILITY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; CHRONIC DISEASE; CYCLOSPORINE; IMMUNOENZYME TECHNIQUES; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; MALE; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RATS; RATS, INBRED STRAINS; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 79960953339     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq790     Document Type: Article

References (37)

1. Halloran PF, Melk A, Barth C. Rethinking chronic allograft nephropathy: the concept of accelerated senescence. J Am Soc Nephrol 1999; 10: 167-181 (Pubitemid 29034957)
2. Paul LC. Chronic allograft nephropathy-a model of impaired repair from injury? Nephrol Dial Transplant 2000; 15: 149-151 (Pubitemid 30064265)
3. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005; 16: 3015-3026 (Pubitemid 44743499)
4. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-1100
5. Joosten SA, Sijpkens YW, van Kooten C et al. Chronic renal allograft rejection: pathophysiologic considerations. Kidney Int 2005; 68: 1-13 (Pubitemid 43181359)
6. Shishido S, Asanuma H, Nakai H et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046-1052 (Pubitemid 36359287)
7. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGFD. Cytokine Growth Factor Rev 2003; 14: 91-98 (Pubitemid 36389523)
8. Fellstrom B, Klareskog L, Heldin CH et al. Platelet-derived growth factor receptors in the kidney-upregulated expression in inflammation. Kidney Int 1989; 36: 1099-1102 (Pubitemid 20049218)
9. Floege J, Hudkins KL, Davis CL et al. Expression of PDGF alphareceptor in renal arteriosclerosis and rejecting renal transplants. J Am Soc Nephrol 1998; 9: 211-223 (Pubitemid 28092069)
10. Savikko J, Kallio EA, von Willebrand E. Early induction of plateletderived growth factor ligands and receptors in acute rat renal allograft rejection. Transplantation 2001; 72: 31-37 (Pubitemid 32652503)
11. Savikko J, Kallio EA, Taskinen E et al. The effect of acute rejection and cyclosporin A-treatment on induction of platelet-derived growth factor and its receptors during the development of chronic rat renal allograft rejection. Transplantation 2002; 73: 506-511 (Pubitemid 34193607)
12. Buchdunger E, Cioffi CL, Law N et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000; 295: 139-145
13. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037 (Pubitemid 32267972)
14. Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056 (Pubitemid 32267975)
15. Savikko J, Taskinen E, von Willebrand E. Chronic allograft nephropathy is prevented by inhibition of platelet-derived growth factor receptor: tyrosine kinase inhibitors as a potential therapy. Transplantation 2003; 75: 1147-1153 (Pubitemid 36513012)
16. Savikko J, von Willebrand E, Hayry P. Leflunomide analogue FK778 is vasculoprotective independent of its immunosuppressive effect: potential applications for restenosis and chronic rejection. Transplantation 2003; 76: 455-458; discussion 471-473 (Pubitemid 37013246)
17. Isoniemi HM, Krogerus L, von Willebrand E et al. Histopathological findings in well-functioning, long-term renal allografts. Kidney Int 1992; 41: 155-160
18. Solez K, Colvin RB, Racusen LC et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753-760 (Pubitemid 351347767)
19. von Willebrand E, Zola H, Hayry P. Thrombocyte aggregates in renal allografts. Analysis with fine-needle aspiration biopsy and monoclonal antithrombocyte antibodies. Transplantation 1985; 9: 258-262 (Pubitemid 15137819)
20. Nankivell BJ, Borrows RJ, Fung CL et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333 (Pubitemid 37509740)
21. Rintala JM, Savikko J, Rintala SE et al. FK778 ameliorates posttransplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts. Nephrol Dial Transplant 2008; 23: 3446-3455
22. Mannon RB. Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 2006; 6: 867-875 (Pubitemid 44356636)
23. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217 (Pubitemid 43323069)
24. Wang S, Wilkes MC, Leof EB et al. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 2005; 19: 1-11 (Pubitemid 40069914)
25. Su EJ, Fredriksson L, Geyer M et al. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 2008; 14: 731-737
26. Rieckmann P. Imatinib buys time for brain after stroke. Nat Med 2008; 14: 712-713 (Pubitemid 351951509)
27. Magro L, Mohty M, Catteau B et al. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. Blood 2009; 114: 719-722
28. Stadler M, Ahlborn R, Kamal H et al. Limited efficacy of imatinib in severe pulmonary chronic graft-versus-host disease. Blood 2009; 114: 3718-3719
29. Kitiyakara C, Atichartakarn V. Renal failure associated with a specific inhibitor of BCR-ABL tyrosine kinase, STI 571. Nephrol Dial Transplant 2002; 17: 685-687 (Pubitemid 34308834)
30. Pou M, Saval N, Vera M et al. Acute renal failure secondary to imatinib mesylate treatment in chronic myeloid leukemia. Leuk Lymphoma 2003; 44: 1239-1241 (Pubitemid 36609120)
31. Foringer JR, Verani RR, Tjia VM et al. Acute renal failure secondary to imatinib mesylate treatment in prostate cancer. Ann Pharmacother 2005; 39: 2136-2138 (Pubitemid 41745965)
32. Gibbons J, Egorin MJ, Ramanathan RK et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 2008; 26: 570-576 (Pubitemid 351264350)
33. Judson IR. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose. J Clin Oncol 2008; 26: 521-522 (Pubitemid 351264343)
34. Thierry A, Dreyfus B, Bridoux F et al. Long-term molecular efficacy and safety of imatinib in a patient with chronic myeloid leukaemia after renal transplantation. Nephrol Dial Transplant 2007; 22: 1791-1792 (Pubitemid 47073798)
35. Gilbert RE, Kelly DJ, McKay T et al. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001; 59: 1324-1332 (Pubitemid 32281220)
36. Lassila M, Jandeleit-Dahm K, Seah KK et al. Imatinib attenuates diabetic nephropathy in apolipoprotein E-knockout mice. J Am Soc Nephrol 2005; 16: 363-373 (Pubitemid 41725131)
37. Iyoda M, Shibata T, Kawaguchi M et al. Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis. Kidney Int 2009; 75: 1060-1070